Cambridge Healthtech Institute’s Inaugural

RNA as a Drug Target

September 18-19, 2019

 

RNA molecules are crucial for delivering cellular information and genetic regulation, but until recently the drug discovery world has emphasized protein drug targets. Our lack of knowledge in RNA biology prevented us from exploring possibilities of RNA drug targets , but with recent advances in technologies such as sequencing, new therapeutic strategies are being explored. Join us at the Inaugural RNA as a Drug Target conference, part of Discovery on Target, as we discuss RNA as a novel target site for therapeutics.

 

Who should attend: Medicinal Chemists, Pharmacologists, Drug Discovery Directors.

 

Coverage will include, but is not limited to:

  • Identifying appropriate target structures
  • Design principles for small molecules and oligonucleotides
  • Development of chemical probes for unique RNA elements
  • High throughput techniques to enhance discovery
  • Applications of compounds that target RNA
  • Case studies of other modalities, RNAi, oligonucleotides to target RNA

 

If you would like to submit a proposal to give a presentation at this meeting, please click here.

 

The deadline for priority consideration is February 27, 2019.

 

All proposals are subject to review by session chairmen and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

For more details on the conference, please contact:
Mana Chandhok

Conference Producer

Cambridge Healthtech Institute

Phone: (+1) 781-972-1350

Email: mchandhok@healthtech.com

 

For partnering and sponsorship information, please contact:
Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286

Email: reymael@healthtech.com



Premier Sponsors

AbCellera
Ablexis Alivamab_stacked

Eurofins

Integral

OmniAb Ligand_Pharmaceuticals